Insights on the Healthcare Industry from the 2012 Legal Asset Report

Perhaps more than any other industry, healthcare companies have scrambled to keep up with the changes brought about by COVID-19. Now that some of the changes made are destined to stay, healthcare companies are taking steps to further innovation.

Burford Capital reports that according to Deloitte’s Healthcare Outlook for this year, doctors are prioritizing preventative care over treating conditions as they arise. Virtual appointments and more readily available data sharing and analytics are increasingly utilized to great effect, and collaborations in developing immunizations and other therapeutics appear to be an integral part of this newer, more modern medical landscape.

Litigation relating to COVID, IP relating to pharma patents, opioid litigation, and other business challenges leave some companies under pressure and seeking solutions. Pandemic-related disruptions have manifested differently across the industry, as revenue was lost when elective care was put off or canceled altogether. This might be good news for some insurers, while others are building affirmative recovery programs—putting insurers in a position to pursue litigation as a plaintiff.

How else are healthcare companies managing corporate litigation assets?

• Increased affirmative recoveries are increasingly popular because they work. Employing third-party portfolio legal funding allows companies to pursue meritorious cases with a minimum of financial risk.
• Adding value and controlling costs should both be included in the commercial targets for healthcare companies. A lack of knowledge or a failure to understand how to apply quantitative analysis to litigation assets can lead to missed opportunities to create increased value.
• When financial departments and legal teams work together, the results can be significant. Developing commercial targets as well as employing better cost control can lead to increased opportunities to generate revenue.